Evidence map›Paper›PMID 28418785›Full record

ArticleStem cells and development2017

Metabolomics Analysis of the Osteogenic Differentiation of Umbilical Cord Blood Mesenchymal Stem Cells Reveals Differential Sensitivity to Osteogenic Agents.

Michail E Klontzas, Spyros I Vernardis, Manolis Heliotis, Eleftherios Tsiridis, Athanasios Mantalaris

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells and development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michail E Klontzas1 Biological Systems Engineering Laboratory, Department of Chemical Engineering and Chemical Technology, Imperial College London , London, United Kingdom .
Spyros I Vernardis1 Biological Systems Engineering Laboratory, Department of Chemical Engineering and Chemical Technology, Imperial College London , London, United Kingdom .
Manolis Heliotis2 Department of Oral and Maxillofacial Surgery, London North West Healthcare NHS Trust, Northwick Park Hospital , London, United Kingdom .
Eleftherios Tsiridis3 Academic Orthopaedic Unit, Aristotle University Medical School , Thessaloniki, Greece .
Athanasios Mantalaris1 Biological Systems Engineering Laboratory, Department of Chemical Engineering and Chemical Technology, Imperial College London , London, United Kingdom .
Imperial College London · GBAristotle University of Thessaloniki · GRLondon North West Healthcare NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) of fetal origin, such as umbilical cord blood MSCs (UCB MSCs), have emerged as a promising cell source for musculoskeletal tissue regeneration because of their higher proliferation potential, lack of donor site morbidity, and their off-the-shelf potential. MSCs differentiated toward the osteogenic lineage exhibit a specific metabolic phenotype characterized by reliance to oxidative phosphorylation for energy production and reduced glycolytic rates. Currently, limited information exists on the metabolic transitions at different stages of the osteogenic process after osteoinduction with different agents. Herein, the osteoinduction efficiency of BMP-2 and dexamethasone on UCB MSCs was assessed using gas chromatography-mass spectrometry (GC-MS) metabolomics analysis, revealing metabolic discrepancies at 7, 14, and 21 days of induction. Whereas both agents when administered individually were able to induce collagen I, osteocalcin, and osteonectin expression, BMP-2 was less effective than dexamethasone in promoting alkaline phosphatase expression. The metabolomics analysis revealed that each agent induced distinct metabolic alterations, including changes in amino acid pools, glutaminolysis, one-carbon metabolism, glycolysis, and tricarboxylic acid cycle. Importantly, we showed that in vitro-differentiated UCB MSCs acquire a metabolic physiology similar to primary osteoblasts when induced with dexamethasone but not with BMP-2, highlighting the fact that metabolomics analysis is sensitive enough to reveal potential differences in the osteogenic efficiency and can be used as a quality control assay for evaluating the osteogenic process.

Indexed as

Cell DifferentiationMetabolomeAlkaline PhosphataseBone Morphogenetic Protein 2Cells, CulturedCitric Acid CycleCollagen Type IDexamethasoneGlycolysisHumansMesenchymal Stem CellsOsteoblastsOsteocalcinOsteonectinUmbilical CordAlkaline PhosphataseBone Morphogenetic Protein 2Collagen Type IDexamethasoneOsteocalcinOsteonectincord bloodmesenchymal stem cellsmetabolismmetabolomicsosteoblastsosteogenesis

Identifiers

PMID28418785
PMCPMC5439454
OpenAlexW2588223795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.